Is Simple Peptide Legit? Its Claims, Lab Reports and Record

Simple Peptide is a Florida-based seller in the online "research peptide" market, and its name draws steady searches from people deciding whether to buy. It sells recovery peptides alongside GLP-1 compounds — retatrutide, tirzepatide and semaglutide among them — all labeled for laboratory research. This page checks three things from primary records: what the company says about itself, whether its lab reports pass a standard checklist, and whether any regulator or court has acted against it. It is not a review and carries no score.

What Simple Peptide says about itself

A banner across the top of every page reads "For laboratory research use only. Not for human or animal consumption." The footer adds that the company "is not a compounding pharmacy or chemical compounding facility as defined under 503A" and "is not an outsourcing facility as defined under 503B," and that its products "are not approved by the U.S. Food and Drug Administration (FDA) for human consumption or medical use." It names its owner as Melex Technologies LLC, with a business address in Delray Beach, Florida. The about page describes a "family-run research materials company" that started small in 2019, fully launched in 2023, and targets "99.7% purity" for incoming raw material, with "99% purity or better" for finished lots "where the molecule supports it."

The 503A and 503B lines are worth reading closely. Those are the two legal routes in federal law for compounded drugs: state-licensed pharmacies compounding for individual prescriptions, and FDA-registered outsourcing facilities⁵. A seller stating it is neither is saying its products are not made under either route — which is consistent with selling chemicals, not medicines.

FDA's position on the research label itself is on the record. In a warning letter to another peptide seller, it wrote: "Despite statements on your product labeling marketing your products as 'RESEARCH USE ONLY'... evidence obtained from your websites establish that your products are intended to be drugs for human use."² Its consumer page on unapproved GLP-1 drugs says the agency has warned companies selling semaglutide, tirzepatide and retatrutide "falsely labeled 'for research purposes' or 'not for human consumption'"³. Federal prosecutors have described research-only disclaimers on another seller's website as "a ruse to avoid FDA scrutiny."⁶⁷ None of those actions involved Simple Peptide. They show how regulators read the label this whole market uses. The site's current sale banner, "25% off GLPs," refers to products in exactly the category FDA's GLP-1 page describes.

Does it publish batch-specific COAs?

Yes, and they are among the more checkable in this market. The company keeps a public certificate archive searchable by product, lot number and accession number. The reports come from Freedom Diagnostics Testing, an outside lab in Franklin, Tennessee, and each carries a search code that pulls up the same document on the lab's own website⁸. We ran three reports through the five checks in our guide to how to verify a peptide COA, and confirmed each code on the lab's look-up.

A September 2026 BPC-157 report names the lot, reports purity of 99.76% by HPLC, confirms identity by LC-MS, and includes endotoxin and microbial results. The copy on the lab's server matches the copy in the seller's archive.

A September 2026 retatrutide report passes the same checks, at 99.95% purity across three samples. Like many reports in this market, its identity line uses a code — "GLP RT" — rather than the drug's name, though the product line names retatrutide. Codes do not change how regulators see a product: FDA has written out another seller's code-named "GLP-3R" as retatrutide and treated it as an unapproved new drug⁴.

The archive goes back well into 2025, and older entries show the market's growing pains: lot numbers follow several different formats, and some early certificates are posted as images rather than PDFs. The search codes we tried, back to February 2026, all worked on the lab's look-up.

A February 2026 semaglutide report is from before the company expanded its testing panel. It has a lot number, 99.483% purity, a chromatogram and a mass spectrum, but no endotoxin or sterility result. The company says reports issued from May 2026 on include sterility, endotoxin, purity and net peptide content — and the newer reports do.

The number most buyers never check: how much is in the vial

The most useful line on these reports is not purity. It is net content — how many milligrams of peptide the lab actually found. Purity tells you what share of the powder is the peptide; net content tells you how much powder there is. Across the reports we read:

• •A 20 mg BPC-157 vial measured 22.28 mg (about 11% over).
• •A 30 mg retatrutide vial averaged 34.17 mg (about 14% over).
• •A 10 mg semaglutide vial from February 2026 measured 9.41 mg; one from December 2025 measured 12.28 mg — a swing of about 30% between two lots sold under the same label.

For a GLP-1 compound, where prescribed doses climb in small steps, a vial that holds a fifth more or less than its label changes every dose drawn from it. This is exactly the variation that a regulated product's manufacturing standards exist to prevent, and it is visible only to buyers who read the report for their own lot.

How to check a report for your own lot

The archive makes this quick, and it is worth doing for every vial:

1. 1.Read the lot number off the vial and search the archive by lot, not by product name. A product search returns many lots, and only one is yours.
2. 2.Open the report and match the lot exactly, character for character.
3. 3.Take the search code to the lab's own look-up page, typed in by hand rather than reached through a seller's link, and confirm the lot and numbers match.
4. 4.Note the date. A report issued before May 2026 will not include endotoxin or sterility results.
5. 5.Read the net-content line and, if you are measuring anything, work from that number rather than the label.

A lot you cannot find in the archive, or a code the lab's site does not recognize, is a lot with no published test behind it.

Enforcement record: what the primary sources show

This section uses only primary records, matched on the company's legal name and its Delray Beach address — never on a similar-sounding name.

• •FDA warning letters. A full-text search of FDA's warning-letter database for Simple Peptide, Melex Technologies and the street address returns no letter¹.
• •DOJ press releases. No Department of Justice press release names the company or its owner LLC.
• •Federal court records. In the CourtListener archive of federal dockets, neither the brand nor Melex Technologies LLC is a party to any case⁹. Cases involving unrelated companies with a similar name were not counted.

No public enforcement action names Simple Peptide. That describes the record; it is not a clearance, since FDA's letters reflect what the agency chose to act on, not everything it has reviewed.

What this means if you are deciding

A clean, checkable report narrows one risk: getting the wrong substance or a badly contaminated lot. It does not change what the substance is, and it says nothing about the questions a prescriber would ask first — whether the drug suits you, what dose to start at, and what to watch for. Retatrutide is an investigational drug whose human data come from clinical trials¹³, and FDA calls retatrutide, semaglutide and tirzepatide sold under research labels unapproved drugs³. BPC-157 sits on FDA's list of bulk substances that may present significant safety risks¹¹. Across this supply chain, testing keeps finding labels that do not match contents — in a JAMA study of 44 products sold online as SARMs, only 23 contained the drug class on the label¹². The "research use only" label itself comes from the labeling rules for diagnostic test kits, not medicines¹⁰. For the warning signs that apply to any seller, see our guide to peptide vendor red flags, and for the legal picture, where to buy peptides and the research-chemical gray zone.

What a licensed prescriber can give you today

If you came here comparing GLP-1 vials, the prescribed versions are the regulated route: a clinician who checks whether the drug suits you, a state-licensed pharmacy, and a dose schedule built for a person. FDA's advice to people buying GLP-1 drugs online is to buy only from state-licensed pharmacies³.

• •Weight loss: prescribed tirzepatide and semaglutide programs are compared in our guides to the best tirzepatide online and the best semaglutide online.
• •Growth-hormone support: sermorelin is prescribed through telehealth clinics — see the best sermorelin online.
• •Recovery: the prescribed options, with anti-doping status, are in our best recovery peptides comparison.
• •Energy and aging: prescribed NAD+ programs are compared in best NAD+ injections.